Patent: 11,591,393
Summary for Patent: 11,591,393
| Title: | Checkpoint blockade and microsatellite instability |
| Abstract: | Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. |
| Inventor(s): | Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian |
| Assignee: | Johns Hopkins University |
| Application Number: | US17/465,101 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,591,393
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | For Injection | 125514 | September 04, 2014 | ⤷ Start Trial | 2041-09-02 |
| Msd International Business Gmbh | KEYTRUDA | pembrolizumab | For Injection | 125514 | September 4, 2014 | ⤷ Start Trial | 2041-09-02 |
| Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | Injection | 125514 | January 15, 2015 | ⤷ Start Trial | 2041-09-02 |
| Msd International Business Gmbh | KEYTRUDA | pembrolizumab | Injection | 125514 | January 15, 2015 | ⤷ Start Trial | 2041-09-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,591,393
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2015346295 | ⤷ Start Trial |
| Australia | 2019201671 | ⤷ Start Trial |
| Australia | 2021202086 | ⤷ Start Trial |
| Canada | 2966660 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
